Virus-like particles: The future of microbial factories and cell-free systems as platforms for vaccine development

William A. Rodríguez-Limas, Karthik Sekar, Keith E.J. Tyo*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

62 Scopus citations

Abstract

Vaccines based on virus-like particles have proved their success in human health. More than 25 years after the approval of the first vaccine based on this technology, the substantial efforts to expand the range of applications and target diseases are beginning to bear fruit. The incursion of high-throughput screening technologies, combined with new developments in protein engineering and chemical coupling, have accelerated the development of systems capable of producing macrostructures useful for vaccinology, gene delivery, immunotherapy and bionanotechnology. This review summarizes the most recent developments in microbial cell factories and cell-free systems for virus-like particle production and discusses the future impact of this technology in human and animal health.

Original languageEnglish (US)
Pages (from-to)1089-1093
Number of pages5
JournalCurrent Opinion in Biotechnology
Volume24
Issue number6
DOIs
StatePublished - Dec 2013

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Fingerprint Dive into the research topics of 'Virus-like particles: The future of microbial factories and cell-free systems as platforms for vaccine development'. Together they form a unique fingerprint.

Cite this